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Background: Women with gestational diabetes mellitus (GDM) and their offsprings are at increased risk of future
type 2 diabetes and metabolic abnormalities. Early diagnosis and proper management of GDM, as well as, postpartum
follow-up and preventive care is expected to reduce this risk. However, no large scale prospective studies have been
done particularly from the developing world on this aspect. The objective of this study is to identify and follow a cohort
of pregnant women with and without GDM and their offspring to identify determinants and risk factors for GDM, for
various pregnancy outcomes, as well as, for the development of future diabetes and metabolic abnormalities.
Methods: This is a prospective cohort study involving pregnant women attending prenatal clinics from urban,
semi-urban and rural areas in the greater Chennai region in South India. Around 9850 pregnant women will be
screened for GDM. Socio-economic status, demographic data, obstetric history, delivery and birth outcomes, perinatal
and postnatal complications, neonatal morbidity, maternal postpartum and offsprings follow-up data will be collected.
Those diagnosed with GDM will initially be advised routine care. Those unable to reach glycaemic control with diet
alone will be advised to take insulin. Postpartum screening for glucose abnormalities will be performed at months 3
and 6 and then every year for 10 years. The offsprings will be followed up every year for anthropometric measurements
and growth velocity, as well as, plasma glucose, insulin and lipid profile. In addition, qualitative research will be carried
out to identify barriers and facilitators for early GDM screening, treatment compliance and postpartum follow-up and
testing, as well as, for continued adherence to lifestyle modifications.
Discussion: The study will demonstrate whether measures to improve diagnosis and care of GDM mothers followed
by preventive postpartum care are possible in the routine care setting. It will also map out the barriers and facilitators
for such initiatives and provide new evidence on the determinants and risk factors for both GDM development and
occurrence of adverse pregnancy outcomes and development of future diabetes and metabolic abnormalities in the
GDM mother and her offspring.Background
Prevalence of diabetes is increasing globally, particularly
in the developing world with China and India contribut-
ing a major part of the increasing burden. A serious con-
cern is that India is projected to have the highest
population of people with diabetes in the world, by 2030
[1]. The rise in prevalence is attributed to aging popula-
tion, urbanization, rising obesity, unhealthy diets and* Correspondence: balajivijayam@gmail.com
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unless otherwise stated.physical inactivity, in addition to the genetic predispos-
ition of South Asians to diabetes [2]. While all these fac-
tors do contribute to the epidemic of diabetes, early life
programming seems to play a facilitator role and prepare
the ground for adult life risk factors to come into play.
The ‘Foetal Origin of Disease’ hypothesis proposes that
susceptibility to adult diseases may be influenced by ges-
tational programming [3], whereby stimuli or stresses
encountered by the foetus at critical or sensitive periods
of development can permanently induce structural, phys-
iological, and metabolic changes, which predispose the in-
dividual to disease in adult life [4].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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encompasses maintaining normoglycaemia in genetically
or otherwise susceptible individuals [5]. Primary preven-
tion strategies like lifestyle modification with or without
pharmacological interventions can delay or prevent the
development of T2DM in persons diagnosed with im-
paired glucose tolerance (IGT) [6,7]. An ideal target for
such preventive interventions are women with history of
gestational diabetes mellitus (GDM) and their children, as
they are at a very high risk of developing diabetes, pre-
dominantly T2DM. GDM is defined as, ‘any degree of
glucose intolerance with onset or first recognition during
pregnancy’ [8,9]. A recent meta-analysis shows that
women with GDM have an increased risk of developing
T2DM (RR 7 43, 95% CI 4 79–11 51). Within 5 years of
an index pregnancy complicated by GDM, women had a
relative risk of 4.69, which more than doubled to 9.34 in
those examined more than 5 years postpartum [10]. A
study from India found that women with GDM had a 3-
fold increased lifetime risk of developing T2DM compared
to pregnant women without GDM 16 years after index
pregnancy [11]. In an Indian population it has been shown
that by 17 years of age, one-third of children born to
GDM mothers have evidence of impaired glucose toler-
ance (IGT) or T2DM [12].
One third (33%) of women with GDM in India give a
history of maternal diabetes [3]. In-utero exposure to
hyperglycaemia has been shown to be associated with in-
creased occurrence of IGT and defective insulin secretory
response in later stages of life, independent of genetic pre-
disposition to T2DM [13]. In addition, children exposed
to maternal diabetes in-utero, are known to have higher
risk of obesity and diabetes compared to their unexposed
siblings, suggesting non-genetic factors for the increased
risk amongst exposed offsprings [13,14]. This compelling
evidence centralizes the role of the intra-uterine environ-
ment in inordinately increasing the risk of future T2DM
and other metabolic abnormalities, and offers unique op-
portunities for primary prevention.
As the age of onset of diabetes is declining and the child
bearing age increasing, it is not uncommon for women to
have previously undiagnosed diabetes when they become
pregnant; it is therefore important that all pregnant
women be tested both early in the pregnancy to rule out
overt diabetes, as well as later on in the 2nd and 3rd tri-
mesters to detect GDM. Since, women with GDM are at a
high risk of developing diabetes 5–10 years postpartum,
follow-up of women with GDM after the delivery is cru-
cial. This is emphasized by the fact that T2DM can be de-
layed or prevented in women with GDM by lifestyle
modifications or modest-intermittent drug therapy [7].
Apart from its relevance in preventing intergenerational
transmission of diabetes, GDM - being one of the most
common medical conditions associated with pregnancy –is also highly relevant for the prevention of adverse preg-
nancy outcomes. Thus identifying women with GDM,
and implementing interventional strategies aimed at con-
trolling glycaemic status has implications for maternal and
neonatal morbidity and mortality through reductions
in abortions, stillbirths, obstructed labour, macrosomia,
shoulder dystocia and pregnancy-induced hypertensive
disorders, pre-eclampsia, postpartum haemorrhage,
neonatal hypoglycaemia, jaundice, infant respiratory
distress syndrome etc.
This article describes the study design and research
methodology for the identification and follow-up of
pregnant women with GDM and their offspring. The
aim is to establish a cohort consisting of pregnant
women in the state of Tamil Nadu to study and under-
stand 1) determinants, e.g. socio-economic status, and
risk factors for the development of GDM, 2) determinants
for achievement of glycaemic control among women diag-
nosed with GDM, 3) differences in pregnancy-related out-
comes among women with and without GDM and their
offsprings, 4) determinants for various postpartum health
indicators among women with GDM and their offspring,
and 5) differences in postpartum health indicators among
women with and without GDM and their offsprings. In
addition to the cohort study, complimentary qualitative
research will be carried out. This comprehensive study will
help shape the public health response to the rising burden
of GDM and diabetes.
Methods
Design
This prospective cohort study is designed to identify
women with GDM, and follow them through pregnancy
and for several years postpartum. A sample size of 1200
pregnant women with GDM is planned. With 13.4% re-
ported prevalence of GDM [15], screening a cohort of at
least 9850 pregnant women is expected to give approxi-
mately 1320 women with GDM. Anticipating a max-
imum dropout of 10%, about 1200 women with GDM
will be available for a follow-up of 10 years. Measures
such as reminder phone calls and house visits will be
employed to ensure a high follow-up rate.
Study setting
Screening for GDM during pregnancy has gradually over
the last couple of years become a routine part of ante-
natal care in Tamil Nadu. The study will be carried out
at three different health centres: Dr. V. Seshiah Diabetes
Care and Research Institute, the Corporation Maternity
Hospital and the Periyapalayam Government Primary
Health Centre. The first centre is a private diabetes hos-
pital located in urban Chennai, which caters mainly to
the middle class population. The other two centres are
government run and cater to the lower income groups
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have previously been used for GDM research [5]. The
government of Tamil Nadu offers free antenatal care ser-
vices through the government run health centres and al-
most all pregnant women in the state have at least three
antenatal care visits and most have an antenatal care
visit in the first trimester. Middle class pregnant women
will usually attend private practicing gyn/obs for ante-
natal care, who will then refer the women for a routine
GDM test at Dr. V. Seshiah Diabetes Care and Research
Institute.
Subject recruitment
All pregnant women attending one of the three centres
will be enrolled in the study when attending GDM
screening at the prenatal clinic at the government health
centres or at Dr. V. Seshiah Diabetes Care and Research
Institute, and undergo preliminary clinical examination.
The recruitment will be conducted by trained field staff.
Prior to the examination, subjects will be briefed about
the purpose of the study, methods (vide infra) to be
adopted and written signed informed consent (Additional
file 1) will be obtained from each participant.
All pregnant women will be enrolled in this study, ir-
respective of their gestational age, parity, age, or socio-
economic status. All women will undergo a test for
GDM, irrespective of whether they have been tested for
GDM previously or not, and the group will be divided in
to those diagnosed with GDM and those with normal
glucose tolerance. Women with known pre-gestational
diabetes will be excluded. A GDM registry will be estab-
lished and study data as described below will be col-
lected from all subjects.
Main exposure and outcome variables
As mentioned, a number of studies are planned based
on this cohort. The key outcome variables will be diag-
nosis of GDM, various adverse pregnancy outcomes
such as macrosomia, stillbirth, congenital abnormality,
pre-eclampsia and postpartum metabolic abnormalities
such as hyperglycaemia, hyperlipidaemia and anthropo-
metric details of both the mother and child. The expos-
ure variables will be various demographic and socio-
economic details, obstetric history including previous
pregnancy complications, anthropometric measurements
and clinical parameters e.g. plasma glucose and lipid
profiles in the various trimesters, treatment plan and
postpartum breastfeeding.
Data collection at recruitment and subsequent follow-up
visits during pregnancy
The data collection will be performed by a team of field
staff who will be trained on methods for data collection, an-
thropometric measurements, sampling of blood specimen,lifestyle and diet counselling, at the centre before the com-
mencement of field work. This is to ensure that each team
member understands and implements the procedure that
he/she is expected to perform thereby reducing the intra-
and inter-observer variability.
A proforma for data collection, including patients’ iden-
tification details, socio-economic status, demographic
characteristics, obstetric history, delivery and birth out-
comes, perinatal and postnatal complications, neonatal
morbidity, maternal postpartum follow-up and the follow-
up data of offsprings, has been developed (Additional
file 2). The reliability of the proforma was tested in an
unpublished pilot study where the proforma was admin-
istered on the same 25 pregnant women by two investi-
gators independently. The inter-observer agreement of
the proforma was very high (Kappa = 0.85; A Kappa
value of >0.8 suggests good agreement between the
observers).
At the time of recruitment/first visit, the pregnant
women’s identification and contact details, socio-economic
status, demographic characteristics and obstetric history
will be recorded. In addition, all study participants will
undertake a knowledge and attitudes questionnaire
(Additional file 3), which will guide health education,
and laboratory and anthropometric measurements will
be recorded. For women recruited in their first and sec-
ond trimester of pregnancy, some of these measurements
will be repeated when they return for a follow-up visit in
the following trimester(s). The study design i.e. the par-
ticipant flow and data collection is depicted in Figure 1
and Table 1.
Laboratory measurements
After an overnight fast blood will be collected for the es-
timation of fasting plasma glucose (PG), following which
all pregnant women will be administered 75 g anhydrous
oral glucose dissolved in 150 ml of water and venous
blood samples collected after 2 h for measuring PG
levels. In the urban centre, blood samples will also be
collected after 1 h of oral glucose administration. In the
semi-urban and rural centres, first hour PG will be esti-
mated using a calibrated glucometer [One touch® select®],
as pregnant women in these areas may object to blood
collection multiple times. Pregnant women will be consid-
ered to have GDM if 2-h PG ≥140 mg/dL (≥7.8 mmol/L),
in accordance with the national policy and the Diabetes in
Pregnancy Study Group in India (DIPSI) recommendation
[16]. Pregnant women with normal glucose tolerance test
in the first visit would undergo a repeat glucose challenge
test around 24 to 28 weeks of gestation. Plasma glucose
will be estimated by enzymatic glucose oxidase-peroxidase
method in the central laboratory of Dr. V. Seshiah
Diabetes Care and Research Institute using Hitachi fully
automated analyzer.
Figure 1 Flowchart of the study.
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sured (see Table 2) from the fasting samples collected at
the same visit(s) when the glucose tolerance test is per-
formed. Lipid profiles and glycated haemoglobin will be
estimated in all pregnant women during the first and
third trimesters. Total cholesterol, triglycerides, low
density lipoprotein-cholesterol, high density lipoprotein-
cholesterol, C-reactive protein and fasting and post
prandial insulin will be estimated in all pregnantwomen. Thyroid stimulating hormone levels will also be
estimated.
Anthropometric measurements
Anthropometric measurements will be recorded for all
pregnant women as described in Chennai urban popu-
lation study [17]. At the urban centre these will be
recorded at the time of laboratory measurements,
whereas in the semi-urban and rural centres these will




Enrolment − General information and identification details.
− Socio-economic and demographic details.
− Obstetric history.
− Fasting & 2 h plasma glucose, 1 h blood glucose,
HbA1c, HB, Thyroid profile, Lipid profile.
− Height, weight, blood pressure.
− Knowledge and attitudes questionnaire.
− Foetal monitoring when possible.
Delivery − Mode of delivery, birth weight, respiratory rate,
ponderal index, APGAR score.
− Hypoglycaemia, shoulder dystocia,
respiratory distress.
− Anthropometric details.





− Fasting and 2 h plasma glucose for the mothers.
− Weight of the mothers.




− Fasting and 2 h plasma glucose for the mothers.
− Weight of the mothers.
− Assessment of depression in the mothers.
1 year postpartum − Breastfeeding practices.
− Fasting and 2 h plasma glucose for the mothers.
− Lipid profile for the mothers.
− Weight of the mothers.
− Assessment of depression in the mothers.
− Weight, height and flank skin fold thickness
of the children.
− Fasting and 2 h plasma glucose for the children.






− Fasting and 2 h plasma glucose for the mothers.
− Lipid profile for the mothers.
− Weight of the mothers.
Every 2nd year
till year 15
− Weight, height and flank skin-fold thickness
of the children.
− Fasting and 2 h plasma glucose for the children.
− Insulin and lipid profile for the children.
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boratory measurements.
Height will be recorded in centimetres with the sub-
jects standing against the wall in an upright position
without footwear using a calibrated stadiometer. Weightwill be measured in kilograms on a calibrated, electronic,
digital weighing scale. Subjects will be requested to wear
light clothing and stand upright without footwear.
Sitting blood pressure (BP) will be recorded from the
right arm using a sphygmomanometer in a sitting pos-
ition. The mean of two BP readings, taken 5 minutes apart
will be recorded. Pregnant women will be categorized as
hypertensive if they were/are on antihypertensive treat-
ment or if they have a systolic blood pressure >140 mm
Hg and/or diastolic blood pressure >90 mm Hg. Diagnosis
of hypertension will be made according to the Joint
National Committee (on prevention, detection, evaluation,
and treatment of high blood pressure) criteria [18].
Prenatal management
Nutritional and lifestyle modification
The nutritional and lifestyle recommendations used in
this study follow the DIPSI guideline [16] and are similar
to those routinely given in the participating health cen-
tres. A diet plan for each woman diagnosed with GDM
will be distributed and explained by the dietician or
trained field staff (Additional files 4 and 5). The diet plan
among other things dictates no or reduced consumption
of sugar and rice and high intake of greens and vegeta-
bles and adequate nourishment to maintain recom-
mended weight appropriate for the gestational week.
The counselling will take into consideration responses to
the knowledge and attitudes questionnaire to ensure that
the necessary information is provided and misconcep-
tions are clarified. Care will be taken to ensure that
pregnant women with GDM adhere to the diet plan
throughout their pregnancy by repeating diet counselling
at each visit. In addition, all women will be recom-
mended 30 minutes of brisk walking every day [19].
Insulin therapy
Pregnant women with GDM who fail to reach the target
2-h PG <120 mg/dL with nutrition therapy within 2
weeks will be advised to take an appropriate dose of in-
sulin in addition to the meal plan. The assessment will
be carried out by the physician at the health centre and
adjustments in the insulin dose will be made throughout
pregnancy if necessary to achieve glycaemic control.
Insulin therapy will by default be continued till delivery.
Foetal monitoring
If foetal ultrasound scanning has already been done
during antenatal care visit, the information regarding
estimated foetal weight, heart rate and amniotic fluid
volume during the first trimester and at 18–20 weeks
of gestation will be collected and recorded. The cer-
vical length, weight gain and foetal abnormalities will
be sought and recorded. Medical records from the
Table 2 Estimation of lipid profile, HbA1c, insulin, c-reactive protein and thyroid stimulating hormone
Parameter Method of estimation Equipment
Total cholesterol CHOD-PAP method COBAS C311 & c501
Triglycerides GPO-PAP method COBAS C311 & c501
Low density lipoprotein-cholesterol Friedewald formula: NA
LDL Cholesterol = (Total Cholesterol) – (HDL- Cholesterol) – (Triglyceride/5)
High density lipoprotein-cholesterol Phosphotungstic acid precipitation and enzymatic colorimetric method COBAS C311 & c501
C-reactive protein Sandwich principle Technique. COBAS C311 & c501
Fasting insulin CLIA technique COBAS C311 & c501
Post prandial insulin CLIA technique COBAS C311 & c501
Thyroid stimulating hormone Electro Chemilumiscent technique COBAS C311 & c501
Glycated haemoglobin (HbA1c) HPLC method Variant II Turbo-2-BIORAD
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inal circumference.
Intrapartum and postpartum management and data
collection
Complications pertaining to the mother during preg-
nancy and delivery, e.g. pre-eclampsia and pregnancy in-
duced hypertension will be assessed and recorded. Other
adverse pregnancy outcomes such as abortion or still-
birth will likewise be recorded.
Intrapartum management
The intrapartum management of pregnant women will be
undertaken as per the protocol of the local hospital in
conjunction with physician, obstetrician and neonatolo-
gist, with main focus on glycaemic control and optimum
blood pressure of the mother in case of GDM. Neonates
will be monitored closely by the attending doctor who will
note down information related to mode of delivery, birth
weight, ponderal index, Appearance Pulse Grimace Activ-
ity Respiration (APGAR) score, shoulder dystocia, respira-
tory distress and hypoglycaemia. This information will be
collected shortly after delivery by the field staff along with
anthropometry details of the infant. In addition, cord
blood will be collected for assessment of insulin, c-peptide
and glucose levels. Early breastfeeding of neonates will be
encouraged for all mothers. Since neonates of mothers
with GDM are at risk of complications like respiratory dis-
tress syndrome, hypoglycaemia, hypocalcaemia and hyper-
bilirubinemia, they will be monitored closely for 24 h after
birth. Macrosomia in the study will be defined as birth
weight above 3.5 kg.
Postpartum management
All pregnant women – both those with GDM and those
without - will be screened for diabetes and have their
PG values assessed postpartum. Appropriate medical
care of mother and child will be taken through educa-
tion and intervention strategies.Postpartum screening for diabetes
Glucose tolerance test will be performed at months 3
and 6, and thereafter once every year for 10 years post-
partum as per the standard guidelines of WHO expert
committee [20]. At the first postpartum visit women
willing to participate in the long-term follow-up will be
required to again sign a consent form, and will be
handed a health card and information sheet with the
contact details of investigators. In addition, lipid profile
will be estimated at one year postpartum and every year
thereafter, in order to ascertain the factors associated
with future development of IGT, obesity, diabetes and
cardiovascular diseases.
Lifestyle interventions
Mothers with GDM will be counselled regarding their
higher risk of developing diabetes and necessity for post-
partum follow-up. Women will be educated through
pamphlets/hand-outs and one to one diet and lifestyle
counselling for them and their children. They will be en-
couraged to continue implementing changes made dur-
ing pregnancy in their diet and physical activity even
after delivery.
In addition to diet counselling, the new mothers, both
those with GDM and those without, will be encouraged
for weight loss if required (BMI > 25). The new mothers
will be encouraged to initiate early breastfeeding and
continue it for ≥1 year. General diet advice for children
of women with GDM will be provided.
Postpartum follow-up
The children of both, mothers with GDM and those
without, will be followed-up for their weight, height,
flank skin-fold thickness, OGTT, insulin and lipid profile
at the age of 1 year and then every second year up to
year 15. In case any markers of risk for diabetes, or car-
diovascular disease, are identified, the mothers will be
educated about preventive measures. If necessary, treat-
ment will be initiated.
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then every year for 10 years, the weight of mothers will
be measured. Also, at 3 months and 6 months post-
partum mothers will be assessed for depression using a
depression questionnaire adopted from Edinburgh post-
natal depression scale (Additional file 6) [21,22]. Women
falling in the depression score will be referred to a
psychiatrist. The same depression assessment along with
knowledge and attitude questionnaire will also be done
one year postpartum. Mothers will be assessed for
breastfeeding (Additional file 7) intensity at 3 months, 6
months, 1 year and 2 years postpartum. They will also
receive counselling on family planning and birth control
as per the local state policy. Subjects lost to follow-up
will be contacted through phone, e-mail and text SMS
or by home visits as a last resort and encouraged to con-
tinue follow-up.
Planned statistical analysis and quality control
All data pertaining to the study population, starting from
their first visit until the last follow-up will be docu-
mented and stored using the Epi Info software. Data will
be analysed using statistical software, SPSS (version 16).
The integrity of data collected will be reviewed weekly
and missing and erroneous data will be corrected imme-
diately. Descriptive analysis will include simple 2×2 ta-
bles, where data on continuous variables are presented
as mean ± standard deviation (SD) and categorical vari-
ables are presented as number (%). Significance will be
assessed at a 5% level. Chi-square/Fisher Exact test will
be used to find the significance of between group differ-
ences in study parameters on categorical scale. In
addition, Student t-test will be used to determine the
significance between the means of two groups for vari-
ous study parameters. When relevant, the odds ratio will
be calculated. Multivariate regression analysis will be
used to explore the relationship between various inde-
pendent variables and the dependent variable; for instance,
between various socio-economic factors, demographic pa-
rameters, obstetric history and various clinical parameters;
and prenatal and postnatal hyperglycaemia.
Complimentary qualitative research
Apart from the establishment of the cohort study, quali-
tative research will also be carried out. This research will
focus on identifying barriers and facilitators for early
GDM screening, treatment compliance and postpartum
diabetes testing, and continued lifestyle modifications.
Pregnant women who have or were supposed to have
attended GDM screening will be interviewed and focus
group discussions with such women will also be orga-
nized. In addition, women diagnosed with GDM will be
interviewed during pregnancy and again postpartum.
The women will be recruited through health care centresin urban and rural areas, and also through village health
nurses in rural areas. Recruitment will be continued
until theoretical saturation has been reached. Moreover,
individual interviews with health care providers as well
as observation at the centres will also be conducted. The
qualitative data will be analysed using content analysis.
Discussion
This cohort study includes pregnant women attending
services for GDM testing at three clinics in greater
Chennai, including an urban private hospital setting, a
semi-urban government hospital setting and a rural gov-
ernment hospital setting. It was previously reported that
the prevalence of GDM using the adapted WHO 1999
guideline as recommended by DIPSI in these areas
ranged from around 10% to 18% [5]. This unique study
will provide important data to investigate the role of
various risk factors for GDM. It is also expected to shed
light on the role of various biochemical, clinical and so-
cial factors on adverse pregnancy outcomes, including
macrosomia. Finally, it will provide much needed details
pertaining to the long-term outcomes in both women
with GDM and their offsprings. To our knowledge, this
is one of the first cohorts established to make such de-
tailed quantitative and qualitative investigations on
GDM in a developing country and the main strength of
this study is its long duration. The need for such re-
search has recently been highlighted by the WHO in
their publication of the new guideline for diagnosing
hyperglycaemia first detected in pregnancy [20].
Though we believe there is a great need for research
like this from developing countries, we also acknowledge
that there will be challenges in implementing such an
ambitious cohort study. One hurdle is that there is no
comprehensive and detailed surveillance system in place
in the state, which may make it difficult to track the
mothers and their offsprings, particularly in the Indian
health system which is a complex intermix of private
and government health care providers and patients float-
ing in and out freely between them. The situation is fur-
ther complicated by the fact that pregnant women tend
to move to their native home for delivery [23] and there-
fore may not be visiting the same prenatal clinic in the
beginning and in the end of their pregnancy. Moreover,
some pregnant women may go to a private clinic to have
ultrasonography, but attend a government clinic for gen-
eral antenatal check-ups.
A number of studies have shown that rates of postpar-
tum follow-up of women with GDM are often at an un-
satisfactory level [24-29]. Studies from Canada and the
US found that women with a history of GDM reported
time pressure, lost requisition, dissatisfaction with health
care services, logistics of accessing care, believing not to
be in need of care, fear of receiving bad news, emotional
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health issues and recent delivery experiences as barriers
for attending postpartum diabetes testing [30,31]. No
such studies have been conducted in India, but experi-
ences from GDM projects supported by the World Dia-
betes Foundation, including projects in India, indicate
the fact that a woman is considered lost in the system
when she is no longer seen by either the obstetrician or
the diabetes specialist. Women being too busy taking
care of the child and doing other household work were
reasons for not attending postpartum follow-up visits
[23]. Acknowledging the challenge of ensuring a high
postpartum follow-up rate, field staff have been trained to
pay particular attention to this and to inform women of
the importance of returning for follow-up. Reminders
through phone, e-mail, SMS or house visits are planned.
In addition, a close collaboration with the maternal and
child health service providers in the areas has been estab-
lished to further ensure a good postpartum follow-up rate
through reminders during visit for the child’s vaccination.
In addition to the cohort study, qualitative research
will be done to compliment the quantitative findings.
The knowledge gained from this combined research will
be used to further improve GDM related detection,
counselling, treatment and postpartum follow-up. The
findings from the study will be used for awareness and
advocacy and further shape and enhance the public
health response to the rising burden of GDM and
T2DM in India and in other developing countries.
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